Leerink Partners downgrades Quanterix to 'market perform' on Akoya deal risks

Brokerage Leerink Partners downgrades diagnostic company Quanterix QTRX.O to "market perform" from "outperform", citing amended deal with Akoya AKYA.O "still distracts from core" and creates challenges in the market

Brokerage also lowers PT to $8 from $12, a 32.2% upside to the stock's last close

Brokerage doubts QTRX can successfully integrate AKYA while dealing with its own supply-chain and tariff issues

AKYA's spatial proteomics business is in a "soft patch" in the market, with 15% revenue drop in 2024, posing an additional challenge for QTRX - Leerink

Adds that QTRX faces another challenge as "tariff risk is modest" but still requires them to reassess and adjust their supply chain amid trade uncertainty

Says QTRX faces "pressures in their core academic markets" and "pharma pullback in funding"